Evidence map›Paper›PMID 26696585›Full record

ReviewHepatology international2016

Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography.

Hitoshi Maruyama, Gamal Shiha, Osamu Yokosuka, Ashish Kumar, Barjesh Chander Sharma, Alaa Ibrahim, Vivek Saraswat, Cosmas Rinaldi A Lesmana, Masao Omata

Abstract readReview
PubMed Publisher
In one paragraph

Review in Hepatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Advances in ultrasound diagnosis in chronic liver diseases.Clinical and molecular hepatology · 2019
    Review
  6. [Consensus on clinical application of hepatic venous pressure gradient in China (2018)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 4 countries.

Hitoshi MaruyamaDepartment of Gastroenterology and Nephrology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuou-ku, Chiba, 260-8670, Japan. maru-cib@umin.ac.jp.
Gamal ShihaEgyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
Osamu YokosukaDepartment of Gastroenterology and Nephrology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuou-ku, Chiba, 260-8670, Japan.
Ashish KumarDepartment of Gastroenterology & Hepatology, Ganga Ram Institute for Postgraduate Medical Education & Research (GRIPMER), Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, 110 060, India.
Barjesh Chander SharmaDepartment of Gastroenterology, GB Pant Hospital, New Delhi, India.
Alaa IbrahimGI/Liver division, GIT Endoscopy Unit, University of Benha, Banha, Egypt.
Vivek SaraswatDepartment of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, 226014, India.
Cosmas Rinaldi A LesmanaDepartment of Internal Medicine, Hepatobiliary Division, Cipto Mangunkusumo Hospital, University of Indonesia, Jawa Barat, Indonesia.
Masao OmataYamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan.
Chiba University · JPBenha University · EGGovind Ballabh Pant Hospital · INMansoura University Hospital · EGRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo · IDSanjay Gandhi Post Graduate Institute of Medical Sciences · INSir Ganga Ram Hospital · INUniversity of Yamanashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Portal hypertension and hepatic fibrosis are key pathophysiologies with major manifestations in cirrhosis. Although the degree of portal pressure and hepatic fibrosis are pivotal parameters, both are determined using invasive procedures. Ultrasound (US) is a simple and non-invasive technique that is available for use worldwide in the abdominal field. Because of its safety and easy of use, contrast-enhanced US is one of the most frequently used tools in the management of liver tumors for the detection and characterization of lesions, assessment of malignancy grade, and evaluation of therapeutic effects. This wide range of applications drives the practical use of contrast-enhanced US for evaluation of the severity of portal hypertension and hepatic fibrosis. The present article reviews the recent progress in contrast-enhanced US for the assessment of portal hypertension and hepatic fibrosis.

Indexed as

Contrast MediaHumansHypertension, PortalLiver CirrhosisSeverity of Illness IndexUltrasonographyContrast MediaCirrhosisContrast agentFibrosisLiverPortal hemodynamicsUltrasound

Identifiers

PMID26696585
OpenAlexW2253854241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.